Skip to main content
Fig. 1 | BMC Gastroenterology

Fig. 1

From: Pharmacotherapy for primary biliary cholangitis: an assessment of medication candidacy and rates of treatment

Fig. 1

Medication candidacy and usage among patients diagnosed with PBC. UDCA– Ursodeoxycholic Acid; OCA– Obeticholic Acid; ALP– Alkaline Phosphatase; ULN– Upper Limit of Normal. Shown are all patients with a diagnosis of PBC who have records within the health system. Patients were stratified on the basis of medication usage and candidacy for OCA. The number of patients in each category is displayed in parentheses. OCA candidacy is considered to be one or more of the following: failure of ALP to decrease to within 1.67 times the upper limit of normal after one year of therapy with UDCA at appropriate weight-based dosing; inability to tolerate UDCA at appropriate weight-based dosing. *Severe liver disease is defined as one or more of the following: Child-Pugh B/C categorization; presence of portal hypertension; history of liver decompensation. Severe liver disease is a contraindication to the use of OCA.

Back to article page